Cerevel Therapeutics (CERE) Revenue & Revenue Breakdown
Cerevel Therapeutics Revenue Highlights
00
Cerevel Therapeutics Revenue by Period
Cerevel Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2015-08-31 | $2.72M | 13.14% |
| 2014-08-31 | $2.40M | -54.15% |
| 2013-08-31 | $5.24M | -2.38% |
| 2012-08-31 | $5.37M | 100.00% |
| 2001-01-01 | - | - |
Cerevel Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Cerevel Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $8.25M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2016-05-31 | $1.42M | 303.13% |
| 2016-02-29 | $351.00K | -62.74% |
| 2015-11-30 | $942.00K | 10.56% |
| 2015-08-31 | $852.00K | -24.27% |
| 2015-05-31 | $1.13M | 227.99% |
| 2015-02-28 | $343.00K | -14.25% |
| 2014-11-30 | $400.00K | 17.65% |
| 2014-08-31 | $340.00K | -57.82% |
| 2014-05-31 | $806.00K | 62.83% |
| 2014-02-28 | $495.00K | -35.12% |
| 2013-11-30 | $763.00K | -14.94% |
| 2013-08-31 | $897.00K | -33.80% |
| 2013-05-31 | $1.35M | 32.20% |
| 2013-02-28 | $1.02M | -47.86% |
| 2012-11-30 | $1.97M | 68.90% |
| 2012-08-31 | $1.16M | 1.39% |
| 2012-05-31 | $1.15M | -131.10% |
| 2012-02-29 | $-3.69M | - |
Cerevel Therapeutics generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Cerevel Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| TVTX | Travere Therapeutics | $145.24M | $62.90M |
| HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| SWTX | SpringWorks Therapeutics | $5.45M | $59.73M |
| IGMS | IGM Biosciences | $2.13M | $516.00K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| NUVL | Nuvalent | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| CERE | Cerevel Therapeutics | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| VTYX | Ventyx Biosciences | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |